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Abstract 
Background 
An easy to use prediction model for long-term renal patient survival, based on only four 
predictors (age, primary renal disease, sex, and therapy at 90 days after the start of renal 
replacement therapy (RRT)), has been developed in the Netherlands. To assess the usability of 
this model for use in Europe, we externally validated the model in ten European countries.  
Methods 
Data from the ERA-EDTA (European Renal Association - European Dialysis and Transplant 
Association) Registry were used. Ten countries that reported individual patient data to the 
registry on patients starting RRT in the period of 1995-2005 were included. Patients under 16 
years of age and/or with missing predictor variable data were excluded. The external validation 
of the prediction model was evaluated for the 10-year (primary endpoint), 5- and 3-year survival 
predictions by assessing the calibration and discrimination outcomes. 
Results 
We used a dataset of 136,304 patients from 10 countries. The calibration in the large and 
calibration plots for 10 deciles of predicted survival probabilities showed average differences of 
1.5%, 3.2% and 3.4% in observed versus predicted 10-, 5-, and 3-year survival, with some small 
variation on country-level. The C-index, indicating the discriminatory power of the model, was 
0.71 in the complete ERA-EDTA Registry cohort and varied according to country level between 
0.70 and 0.75. 
Conclusions 
A prediction model for long-term renal patient survival developed in a single country, based on 
only four easily available variables, has a comparably adequate performance in a wide range of 
other European countries. 
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Introduction 
End stage renal disease (ESRD) is a major health problem with high mortality rates, affecting 
approximately 1000 patients per million population (pmp) in European countries1. The overall 
yearly unadjusted incidence of new ESRD patients starting renal replacement therapy (RRT) is 
over 100 patients pmp.  
For nephrologists it could be helpful to be able to predict long-term survival chances for all 
patients starting with RRT to support initial patient counseling. As it is unclear at therapy 
initiation whether a patient will stay on dialysis or subsequently receive a kidney transplant, it is 
desirable to use a model for overall survival prediction after the start of RRT, irrespective of 
treatment. Most existing prediction models are focused on dialysis survival until transplantation2, 
survival on the kidney transplant waiting list3;4 or patient survival after renal transplantation5;6, or 
are designed for a specific patient group7, and therefore cannot be used for overall RRT survival 
prediction. In 2013, a straightforward model to predict renal patient survival from the start of 
RRT was developed, based on a cohort of incident RRT patients from 1995-2005 in the 
Netherlands8. It predicts 10-year survival based on four commonly available predictors: age at 
the start of RRT, sex, primary renal disease (PRD), and mode of renal replacement therapy at 
90 days (hemodialysis (HD), peritoneal dialysis (PD), or transplantation). Unlike the existing 
models, this model predicts overall survival from the start of RRT, irrespective of whether 
patients will change treatment modality in a later stage or not.  
A general survival prediction model is desirable for patients to understand the survival 
implications of ESRD and it can be used for shared patient-physician discussion of future 
treatment perspectives, like the consideration of conservative care as an alternative for starting 
dialysis. Furthermore, a survival prediction model could be useful in research for patient 
selection, group comparisons, or for patient stratification according to survival risk in clinical 
trials. Although for individual patient survival predictions it is preferable to take additional clinical 
parameters into account if available, as concluded in a later study9,we think that the original 
straightforward registry model might be very valuable for group comparisons in studies, 
countries, or in periods of time, and for risk stratification or selection purposes in (etiologic) 
studies. Therefore this study has been performed. 
In order to understand whether this prediction model developed in a patient group from one 
country is also suitable for use in other countries, it is essential to explore its generalizability in 
an external validation study10. The predictive performance of the model in the Netherlands 
appeared to be adequate, as demonstrated by internal validation outcomes (good calibration 
results as well as discrimination (C-index: 0.720))8. However, internal validation merely relates 
to the “reproducibility” of results, while the usability of the prediction model in another country is 
a question of “transportability” of the model11. As countries differ in dialysis and transplantation 
possibilities (e.g. access to (home) dialysis, and possibility for renal transplantation (with a living 
or deceased donor)) as well as in patient population characteristics, this could influence survival 
prediction. In this external validation study, we therefore assessed the performance of the model 
as a European renal patient survival prediction model, using data from the European Renal 
Association - European Dialysis and Transplant Association (ERA-EDTA) Registry. 
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Subjects and methods 
We used ERA-EDTA Registry data from ten European countries with national or regional 
registries providing individual level patient data on patients who started RRT between 1995 and 
2005. Like in the original model, 90 days after the start of RRT was used as baseline, to exclude 
acute patients and to ensure enough time to switch to the intended therapy modality. We 
included last available follow-up information in the ERA-EDTA Registry until 1/1/2014. We 
excluded the country where the model was developed (the Netherlands) and countries with less 
than 1000 incident patients in our period of interest. The remaining countries that were included 
in the validation study are: Austria, Belgium (data from the Dutch-speaking and French-
speaking Belgian Registry), Denmark, Spain (data from the regional registries of Andalusia, 
Aragon, Asturias, Basque country, Catalonia, Cantabria, Castile and León, Castile-La Mancha, 
Extremadura, Valencia), Finland, France, Greece, Norway, Sweden, and the United Kingdom 
(data from the UK Renal Registry and the Scottish Renal Registry). Most countries had 100% 
completeness in the whole study period, with the exception of Spain (coverage increasing from 
53% in 1995 to 68% in 2005), France (coverage increasing from 17% in 2002 to 55% in 2005), 
and the UK (coverage increasing from 9% in 1995 to 89% in 2005). We included the patients 
that were at least 16 years old at the start of RRT. We excluded patients that stopped renal 
replacement therapy within 3 months after the start of RRT, including patient death, (N=96, 
0.07%) and patients with missing values on one or more of the remaining prediction variables 
(833 patients with missing PRD, 0.6%). The events from 90 days after the start of RRT till death 
or end of the study were analyzed (1/1/2014); the follow-up period was maximized at 10 years. 
This resulted in a dataset of 136,304 patients. 
The original model8 was developed to predict 10-year patient survival from 90 days after the 
start of RRT. It was based on age at the start of RRT, primary renal disease (PRD), sex, and 
therapy at 90 days. The formula for the survival probability at time t, S(t), is S(t)=exp(-H(t)). Here 
H(t) is the cumulative hazard that is calculated from the baseline hazard (H0) as 
H(t)=H0(t)*exp(prognostic  index). The prognostic index can be calculated, using the values of 
the four predictors for a specific patient (see table 1) together with their parameter estimates. 
The primary endpoint of interest was 10-year survival; additionally we evaluated the 
performance of the model for 5 and 3-year survival.  
We analyzed the performance of the model both in the total ERA-EDTA Registry cohort, as well 
as in the separate countries (anonymously). In order to be transparent and enhance the 
usability of the model, we followed the recently published TRIPOD checklist12;13. In table 1 we 
therefore provide the renal patient survival prediction model which was also published in BMC 
Nephrology 20138. The performance of the prediction model was evaluated by assessing both 
calibration and discrimination. Calibration is the agreement between the probability of 
developing the outcome of interest within a certain time period (in our case 10-, 5- and 3-year 
survival) as estimated by the model and the observed outcome frequencies14. Measures to 
represent calibration in our study are the calibration in the large, calibration plots and calibration 
slopes. “Calibration in the large” is the overall calibration, measured as the observed versus 
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predicted survival for the complete patient cohort. The calibration plot is a graphical method to 
express calibration, by plotting the observed outcome frequencies against the mean predicted 
outcome probabilities, within subgroups of participants that are ranked by increasing estimated 
survival probability14. Ideally the plots follow a 45 degree line, with an intercept of 0 and a slope 
of 115. This is also reflected in the calibration slope, which represents the outcome of a Cox 
regression analysis with the prognostic (risk) index as the only predictor15 and is thus ideally 
equal to 1. Discrimination is the ability of a model to distinguish individuals who experience the 
outcome from those who remain event free14. The concordance index (C-index) is the most 
widely used measure to evaluate discrimination. For a Cox model it represents the chance that, 
given two individuals, the model assigns a higher risk score to the one that develops the event 
of interest in the shortest period of time. A C-index of 0.5 indicates no discriminative power and 
a C-index of 1 indicates perfect discriminative power16. A C-index of 0.7 is considered 
reasonable and a C-index of 0.8 is considered good.  
Because age is a strong predictor for survival, we performed an additional sensitivity analysis, 
stratifying calibration and discrimination analyses by age. For comparison of model performance 
we also stratified by sex. Further, as some countries only had good data completeness in more 
recent years, we stratified the calibration and discrimination analysis by starting year of renal 
replacement therapy. 
Results 
The distribution of the prediction model variables (age at the start of RRT, sex, primary renal 
disease (PRD) and the therapy at 90 days) over the 10 European countries that are used in our 
external validation study are shown in table 2. Most variation between countries as well as 
between validation and development cohort is seen in the distribution of PRD and therapy at 90 
days.  
The calibration in the large for the prediction model in the ERA-EDTA Registry cohort show 
adequate results, with a difference of 1.5%, 3.2% and 3.4% in observed versus predicted 10-, 5- 
and 3-year overall RRT survival respectively. The calibration plots for 10 deciles of predicted 
survival for 10-, 5- and 3-year survival are shown in Figure 1. 
The calibration results of the prediction model at the country level show varying results; in 5 
countries (countries 1-5) the observed and predicted survival probabilities are similar with an 
overall difference of < 1% (Figure 2), so the performance of the original model is good. In the 
other 5 countries the predicted survival probabilities are either slightly higher (country 8) or 
slightly lower (countries 6, 7, 9, and 10). The average absolute difference between observed 
and predicted survival over the countries is 3% (0-8%) for 10-year survival, and 4% (0-9%) for 
5- and 3-year survival. 
The calibration slope, with the prognostic index as the only predictor, is 0.995 for the complete 
ERA-EDTA Registry cohort. For the separate countries the slopes differ from 0.922 till 1.088, 
which is close to the ideal 1. 
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The discrimination for 10-year survival, expressed as the C-index, shows adequate performance 
of the model, with values between 0.70 and 0.75 (Figure 3) for the 10 different countries and 
0.710 (95% CI: 0.708-0.712) for the complete ERA-EDTA Registry cohort. 
Stratified calibration and discrimination results (Table 3) show that within the different age 
groups discrimination was moderate. Discrimination was best in the patients aged younger than 
65, and 10 year calibration was best for the oldest age categories. Model performance in the 
different sexes is similar. Further this stratified sensitivity analysis shows that model 
performance slightly deteriorated in time. 
 
Discussion  
With this study we examined the external validity of a previously published renal patient survival 
prediction model based on four commonly available variables. The model performance in ten 
European countries reporting to the ERA-EDTA Registry is adequate, with an overall C-index of 
0.71 and an average 10-year calibration difference of 1.5%. The model performance for the long 
term survival prediction is slightly better than the short term survival prediction, as could be 
expected as the model has been developed for 10-year survival. Although age is the strongest 
predictor, the model still performs well within the youngest age strata (below 65 years of age). 
This indicates that the other three predictors add discriminating value. The fact that these 
external validation outcomes are similar to the internal validation results in the country where 
the model was developed indicates the robustness of the model. 
These external validation outcomes are remarkable, taking into account the many differences 
between European countries in ESRD patient characteristics and treatment1;17-21, as well as 
mortality rates on dialysis22.  If the model would be influenced by differences in the standard of 
care between countries, such as differences in the percentage of living donor transplants, 
quality of donated kidneys, or patients starting RRT at earlier stages of disease, this would 
directly be reflected by significant difference in outcome.  On the other hand, if differences are a 
consequence of population differences that are either directly or indirectly covered by the model, 
it will not impact model performance.  
The model corrects for differences in patient age, sex, PRD and therapy at 90 days after the 
start of RRT, as these are part of the prediction model. Indirectly the model probably also partly 
corrects for differences in patient condition, as some of the model variables (like PRD, therapy 
and age) are related to patient condition (e.g. hypertension, BMI and cardiovascular disease). 
Next to clinical variation, there are other differences that might affect ESRD patient care and 
survival such as, human and environmental factors (dietary habits23, smoking, physical activity24, 
socioeconomic status25 and birth weight26, healthcare policies27 and genetic differences28) and 
access to the waiting list and renal transplantation. Stel et al.29 conclude from a study in four 
European countries that variation in transplantation rates may be due to a combination of 
factors, including legislation, donor availability, transplantation system organization and 
infrastructure, wealth and investment in health care, as well as underlying public 
attitudes/awareness to donation and transplantation. The fact that reimbursement strategies 
play a role has been confirmed by a study among 5 European countries, the United States and 
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Canada30. Finally, Kramer et al. have shown that macroeconomic factors as well as the intrinsic 
mortality of the dialysis population are associated with differences in the mortality on dialysis 
between countries22. Nevertheless, despite the fact that there probably are factors that influence 
renal patient care and the mortality on RRT, which are not covered by the model, we have 
shown that the renal patient survival prediction model is applicable in a wide range of countries. 
The many differences of the ERA-EDTA Registry cohort compared to the Dutch model 
development cohort actually makes it a very suitable data set for external validation, which in 
itself is a major strength of this study.  
Our validation study shows a comparably sufficient but moderate discriminative power (C-index: 
0.71) of the prediction model in other European countries as was also the case in the Dutch 
cohort 8. This indicates that there is room for improvement. In 2013 we showed, based on data 
from the Netherlands Cooperative Study on Adequacy of Dialysis treatment (NECOSAD) how 
the original survival prediction model could be improved by adding more clinical data9. 
Especially the reclassifications at patient level implied that individual survival probability is 
influenced substantially by the clinical condition of the patient, so an extended model is 
preferably used for individual survival prediction, as an objective predicted survival estimator, 
next to expert opinion. However, as many countries do not register the required additional data 
on a regular basis yet, it is not possible to externally validate an extended prediction model in a 
wide spectrum of European countries. This may be different in the future. Although the validated 
model is less suitable to be used to predict individual patient survival, the validated renal patient 
survival model can be used by European countries to predict objective survival chances for 
groups of patients, to compare risk groups in different studies, or for risk stratification/selection. 
For example, the model can be used to select patients with a predicted 10-year mortality risk 
over 60% to participate in a study, or the model can be used to demonstrate time trends in the 
incident patient populations in a country by differentiation on risk group (defined by specified 
ranges of mortality rates). As has been pointed out in the two manuscripts describing the 
previous models, it is important to note that the model is not recommended for basing clinical 
treatment decisions8,9, as prediction models do not prove causality, and the predictor “treatment 
at 90 days” is merely a proxy for patient condition.  
The strength of this study is the validation of the renal patient survival model in ten different 
European countries, with good or acceptable results in all of these countries. Since we observed 
some variation at country-level, this study also stresses the importance of external model 
validation in more than just one country. External validation limited to one single country could 
lead to over- or underestimated model performance, when the mortality rate in this population is 
different from the reference population10;31. Based on our aim to externally validate the original 
prediction model, we have evaluated this model without any adjustments. Our validation results 
show good discrimination, and only slightly inferior calibration outcomes in some countries. 
Therefore in our opinion, model adjustment was not necessary. However, when the presented 
prediction model is used in another population with differing mortality rates resulting in 
inadequate calibration results, it would be recommended to recalibrate the model by adjusting 
the baseline hazard, using actual population data, as described by Toll et al.32. In fact, a 
purpose of future research could be to update the model based on European data to optimize 
performance in this population and to establish a European model, possibly even with country 
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as a predictor on top of the four predictors currently used. This might further increase the 
usefulness of the RRT survival prediction model in other European countries. Depending on the 
proposed use of the new model, it might also be considered to develop a risk chart to estimate 
survival chances for different risk groups. In either case  external validation of the newly 
developed model is needed again. 
Despite the fact that the prediction model has shown to be valuable in this external validation 
cohort, there are still some study weaknesses to be noted. The most important limitation of the 
study is that the model has only been validated in other countries, but not in another period of 
time. In our study this was not possible, since a more recent cohort does not have 10 years of 
follow-up yet. However, knowing that RRT population and treatment possibilities as well as 
treatment quality and survival21 change over time, regular evaluation, and possible recalibration 
(as suggested earlier for other populations), of the model is recommended. A second limitation 
of this study is that for some countries we validated our results on patients from only a limited 
number of years or from a limited number of regions, which might introduce selection bias and 
influence calibration and discrimination outcomes. Although that might introduce differences at 
country level, we don’t think that this changes the conclusions of the validation study. In fact 
model performance might be slightly underestimated in these countries, and for the complete 
ERA-EDTA Registry cohort, as model performance is more likely to deteriorate in other periods 
of time, as pointed out in the previous limitation, and confirmed by the results of the analyses 
stratified by time.  Finally we should mention the fact that the model uses mainly very 
straightforward variables, except for the PRD. There might be difficulties to adequately (and 
uniformly) describe the patient’s disease. However, the PRD with the most influence on survival 
(diabetes) is relatively easy to detect.  
In conclusion, our external validation study shows that a straightforward prediction model for 
long term patient survival on RRT developed in a single country, based on only four easily 
available variables, has a comparably adequate performance in a wide range of European 
countries participating in the ERA-EDTA Registry.  
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TABLES 
Table 1:  Validated RRT survival prediction model as published in BMC Nephrology8 
Patient characteristics   Parameter estimate* 
Age (per year) 
 
0.054 
Primary renal disease  
  
 
Glomerulonephritis Reference 
 
Cystic kidney disease -0.280 
 
Renal vascular disease 0.331 
 
Diabetes 0.767 
 
Other diseases 0.407 
 
Unknown 0.296 
Therapy at 90 days  
  
 
Hemodialysis Reference 
 
Peritoneal dialysis -0.131 
 
Kidney transplantation -1.634 
Male sex  0.067 
Baseline hazards     
1 year 
 
0.003 
3 year 
 
0.010 
5 year 
 
0.017 
7 year 
 
0.024 
10 year   0.033 
* prognostic index of a patient: the sum of (the product of) parameter estimates 
The survival probability at a certain time point, S(t) can be calculated from the prognostic index and the baseline hazard, using the 
following equation: S(t)=exp(-H0(t)*exp(prognostic  index)).  
E.g. a male 55 year old patient with Diabetes, that started on HD has a prognostic index of ((55 year *0.054=2.97)+0.767 (PRD 
diabetes) +0.067 (male))=3.804; 
The 10-year survival prognosis is: exp(-0.033*(exp(3.804)))= 23%  
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Table 2: Distribution of prediction variables in ERA-EDTA Registry validation cohort; countries (random order) and total 
external validation cohort, compared to the development cohort8 
Country A B C D E F G H I J 
Total 
validation 
cohort 
Development 
cohort 8 
Age group % 
          
  
16-45 14.5 10.9 17.2 15.2 19.2 11.3 12.5 19.3 14.5 19.3 15.1 17.6 
45-65 39 30.1 38 33.2 41.3 28 31.1 33.8 33.3 34.3 33.4 36.9 
65-75 27.9 30.5 27.1 31.1 26.7 28 34.6 25 26.6 26.9 29.3 28.4 
75+ 18.6 28.5 17.6 20.5 12.8 32.8 21.8 21.9 25.5 19.6 22.2 17.2 
PRD %                       
Glomerulonephritis 14.4 11.9 12.3 14.6 14.5 14.1 15.1 21.5 16.2 13.7 14.4 12.5 
Cystic kidney disease 4.5 5.4 6.5 7.3 9.3 7.1 5.1 8.9 6.3 7.2 6.6 8.8 
Renal vascular disease 16.2 22.7 13.1 17.4 5.8 24.5 12.2 25.2 10.9 11.7 15.8 25.2 
Diabetes 32.1 22.8 23.2 19.1 34.4 21.9 25.4 13.5 24.6 19.8 22.6 16.6 
Other diseases 21.7 28.8 24.8 20.4 24.8 22.5 14.9 27 31.1 25.8 23.4 21.8 
Unknown 11.1 8.4 20.1 21.1 11.2 10 27.2 3.9 10.9 21.8 17.2 14.9 
Therapy at 90 days (%) 
          
  
Hemodialysis 88.7 86.9 64.5 86.7 70.5 81.7 88 68.6 64.1 65.3 78.5 65.5 
Peritoneal dialysis 9 11.6 31.6 11.9 28.3 15.7 11.4 17.9 31.8 31.8 19.1 31.7 
Transplantation 2.3 1.5 3.9 1.5 1.2 2.6 0.6 13.5 4.1 3 2.5 2.8 
Sex, % male 60.5 58.1 63.1 61.3 62.5 60.9 61.5 67 64.3 61.1 61.4 61.1 
 
Table 3: Stratified calibration and discrimination results 
 
 
CALIBRATION DISCRIMINATION 
N 
PRED 
3Y 
surv. 
OBS  
3Y 
surv. 
Diff.  
3Y 
surv. 
PRED 
5Y 
surv. 
OBS  
5Y 
surv. 
Diff.  
5Y 
surv. 
PRED 
10Y 
surv. 
OBS 
10Y 
surv. 
Diff. 
10Y 
surv. C-index CI-low CI-high 
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Age group              
16-45 20659 0.913 0.909 0.35% 0.856 0.865 -0.98% 0.744 0.778 -3.34% 0.701 0.694 0.708 
45-65 45507 0.736 0.752 -1.59% 0.597 0.625 -2.82% 0.389 0.422 -3.27% 0.660 0.657 0.663 
65-75 39901 0.514 0.560 -4.61% 0.325 0.366 -4.07% 0.126 0.122 0.44% 0.572 0.569 0.575 
75-100 30235 0.342 0.413 -7.13% 0.166 0.207 -4.08% 0.038 0.031 0.63% 0.551 0.547 0.554 
Sex              
F 52674 0.611 0.645 -3.39% 0.462 0.496 -3.35% 0.290 0.306 -1.63% 0.710 0.707 0.713 
M 83630 0.610 0.644 -3.46% 0.460 0.491 -3.13% 0.287 0.301 -1.37% 0.710 0.708 0.712 
Starting year RRT 
             1995 7200 0.656 0.646 0.96% 0.512 0.500 1.23% 0.334 0.311 2.30% 0.727 0.720 0.734 
1996 7515 0.644 0.644 -0.04% 0.498 0.499 -0.13% 0.320 0.301 1.85% 0.714 0.707 0.721 
1997 8541 0.646 0.648 -0.17% 0.501 0.493 0.79% 0.323 0.312 1.03% 0.714 0.708 0.721 
1998 9994 0.635 0.651 -1.64% 0.487 0.494 -0.65% 0.310 0.300 0.97% 0.716 0.710 0.722 
1999 10565 0.629 0.646 -1.71% 0.481 0.493 -1.23% 0.304 0.307 -0.25% 0.712 0.705 0.718 
2000 11372 0.620 0.635 -1.54% 0.471 0.486 -1.57% 0.295 0.297 -0.22% 0.712 0.706 0.718 
2001 12283 0.609 0.641 -3.25% 0.459 0.485 -2.56% 0.286 0.293 -0.71% 0.710 0.704 0.715 
2002 14394 0.602 0.634 -3.17% 0.452 0.489 -3.71% 0.279 0.307 -2.78% 0.715 0.709 0.720 
2003 15814 0.594 0.643 -4.90% 0.443 0.490 -4.74% 0.272 0.301 -2.90% 0.709 0.704 0.714 
2004 18464 0.587 0.646 -5.96% 0.436 0.492 -5.58% 0.267 0.295 -2.73% 0.707 0.702 0.712 
2005 20162 0.580 0.653 -7.34% 0.428 0.504 -7.57% 0.261 0.331 -6.99% 0.705 0.701 0.710 
PRED=predicted, OBS = observed, Diff.=difference, 3Y/5Y/10Y= 3/5/10 year,  CI-low = confidence interval lower limit, CI-high = confidence interval higher 
limit 
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Legends to figures: 
Figure 1: calibration plots for 10-, 5- and 3-year survival per decile of predicted survival for the complete ERA-EDTA 
Registry cohort 
Figure 2: calibration in the large for 10-, 5- and 3-year survival per country, sorted by overall performance (high-low) 
Figure 3: discrimination (C-index) outcomes for 10-year survival per country (sorted like figure 2) 
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FIGURES 
 
Figure 1: calibration plots for 10-, 5- and 3-year survival per decile of predicted survival for the complete ERA-EDTA 
Registry cohort 
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Figure 2: calibration in the large for 10-, 5-, and 3-year survival per country, sorted (different from table 2) by overall 
performance (high-low; “overall performance” is the average performance over the 3 periods of time) 
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Figure 3: discrimination (C-index) outcomes for 10-year survival per country (sorted like figure 2) 
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